Mark Cuban built a $5.8 billion fortune buying and selling assets that others undervalued. In January 2022, he turned that […]
Mark Cuban’s Generic Drug Play: Who Gets Disrupted First? Read Post »
The press release drops at 7 a.m. Eastern. A mid-cap biotech has just signed a license agreement with a major
Patent Deals Predict Biotech Hiring: How to Read Licensing Signals Before the Jobs Post Read Post »
The molecule did not change. The price did. When AstraZeneca introduced esomeprazole — branded as Nexium — in 2001, it
Reformulated Drugs, Real Money: How Pharma Prices Its Way Past Patent Cliffs Read Post »
The real disruption isn’t lower prices—it’s visible margins Pharmaceutical executives have spent the better part of two decades preparing for
Drug Pricing Transparency Is More Dangerous Than Price Cuts Read Post »
Mark Cuban did not build a pharmacy. He built a mirror and pointed it at an industry that had never
The difference between a blockbuster drug that earns another five years of protected revenue and one that faces generic competition
How Pharma Companies Track IND/NDA Dates to Win Global Patent Extensions Read Post »
The difference between a blockbuster drug that earns another five years of protected revenue and one that faces generic competition
How Pharma Companies Track IND/NDA Dates to Win Global Patent Extensions Read Post »
How inhalers, injectables, and drug-device combinations are reshaping generic drug strategy — and what it takes to win. Abbreviated New
Cracking Complex Generics: The Bioequivalence Playbook That Gets ANDAs Approved Read Post »
Track drug development pipelines and patent filings to surface passive candidates six to eighteen months before your competitors do. When
The Patent Clock: How to Find Pharma’s Best Talent Before They Know They’re Looking Read Post »
Get fresh news and insights, drug patent expirations & more…
